Alx Oncology Holdings (ALXO) Cash & Current Investments (2019 - 2026)

Alx Oncology Holdings' Cash & Current Investments history runs 8 years deep, the most recent figure standing at $140.3 million for Q1 2026.

• In Q1 2026, Cash & Current Investments rose 43.44% year-over-year to $140.3 million; the TTM figure through Mar 2026 stood at $140.3 million (up 43.44% YoY), while the FY2025 annual figure was $44.8 million, down 64.94% from the prior year.
• Cash & Current Investments came in at $140.3 million for Q1 2026 at Alx Oncology Holdings, up from $44.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $316.6 million in Q1 2022 to a low of $44.8 million in Q4 2025.
• A 5-year average of $176.9 million and a median of $157.4 million in 2024 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments slumped 64.94% in 2025 and jumped 43.44% in 2026, its largest moves.
• Alx Oncology Holdings' Cash & Current Investments stood at $266.2 million in 2022, then tumbled by 31.36% to $182.7 million in 2023, then sank by 30.09% to $127.8 million in 2024, then plunged by 64.94% to $44.8 million in 2025, then soared by 213.29% to $140.3 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $140.3 million, $44.8 million, and $60.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison